Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity ATLANTA, GA - June 8, 2026 ...
Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to ...
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) ...
Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired ...
Morning Overview on MSN
Scientists found a hidden pocket on a cancer protein that drugs were never able to grip, opening a path to a new class of precise tumor blockers
Researchers have mapped a previously unseen drug-binding pocket on PKMYT1, a kinase tied to cancer cell division, using X-ray ...
Morning Overview on MSN
Cells that double their DNA through failed division survive far better than those from botched chromosome splits, a clue to how some cancers take hold
Cells that acquire a doubled genome after a failed division step survive and proliferate far more effectively than cells left ...
Fragmented subspecialty care and underbuilt survivorship pathways risk overwhelming primary care as the survivor population ...
Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.
Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results